The goal of this clinical trial is to learn if using calcium sulfate beads that contain vancomycin (an antibiotic) and pain-relieving medicines during spine surgery can improve recovery compared to standard care with intravenous (IV) morphine and local pain medicines.
Researchers want to know if the sustained release formulation of morphine from these calcium sulfate beads affect:
* Postoperative length of stay
* Postoperative pain scores
* Postoperative narcotic analgesic requirements
All participants in this study will already be scheduled to have spine surgery as part of their regular medical care. During surgery, participants will be assigned to receive either intraoperative placement of calcium sulfate beads with vancomycin alone or vancomycin with morphine and bupivacaine. All patients will still have access to standard of care with IV and PO pain regimens. Participants will then be followed after surgery to measure their pain, recovery, and medication use.
Participation is voluntary, and choosing not to join will not affect a person's medical care.

Start Date01 Jan 2027

Sponsor / Collaborator

The Massachusetts General Hospital

NCT06794944

/ Not yet recruitingPhase 4IIT

Use of Fidaxomicin Compared to Vancomycin for Decolonization of C. Difficile in Patients With Inflammatory Bowel Disease

This is a randomized, double-blind study to assess the safety and efficacy of fidaxomicin compared to vancomycin for decolonization of C. difficile in IBD patients. A total of 60 patients who meet eligibility criteria will be randomized 1:1 to either the fidaxomicin or vancomycin arm. The vancomycin arm will receive a dose of 125 mg PO q 6 hours for 10 days. The fidaxomicin arm will receive 200 mg PO BID for 10 days. In order to ensure blinding, both antibiotics will be concealed in opaque 00 capsule shells. In addition, those in the fidaxomicin arm will receive 2 placebo capsules so that all participants will receive 4 capsules daily for 10 days. Microbiome assessment and C. difficile testing will be performed at baseline, day 5, day 10, and weeks 4, 8, and 26.

Start Date01 Sep 2026

Sponsor / Collaborator

The Brigham & Women's Hospital, Inc.

NCT07646223

/ Not yet recruitingPhase 2IIT

The Efficacy of Oral Vancomycin Therapy in Managing Different Phenotypes of Paediatric Inflammatory Bowel Diseases by Correlating Treatment Response to Commensal Microbiota Composition and Function

The goal of this clinical trial is to learn how oral vancomycin therapy may contribute in treating paediatric inflammatory bowel disease, particularly atypical ulcerative colitis and PSC-associated colitis. It will also give more information on how this treatment affects gut microbiota and metabolism.
The main questions it aims to answer are:
1. Does oral vancomycin improve disease activity and lead to remission (based on symptoms, biomarkers, and endoscopy findings)?
2. How does oral vancomycin change gut metabolism?
3. Does different types of colitis respond differently to oral vancomycin?
Researchers will compare children receiving oral vancomycin plus standard therapy to those receiving standard therapy alone. The gut metabolisim before and after oral vancmycin will also be compared, as well as to healthy controls and children with typical ulcerative colitis.
Participants will:
1. Take oral vancomycin (if assigned) together with conventional treatment for at least 3 months and up to 12 months depending on response
2. Visit the clinic approximately every 3 months for checkups, tests, and monitoring
3. Provide blood, stool, and saliva samples to study disease activity and microbiota activity
4. Undergo clinical assessments such as symptom scoring, imaging, and possibly endoscopy
5. Complete questionnaires about quality of life
6. Be monitored for side effects and treatment response throughout the study period

Start Date01 Aug 2026

Sponsor / Collaborator

Tampere University Hospital

[+2]

100 Clinical Results associated with Vancomycin Hydrochloride

100 Translational Medicine associated with Vancomycin Hydrochloride

100 Patents (Medical) associated with Vancomycin Hydrochloride

35,603

Literatures (Medical) associated with Vancomycin Hydrochloride

31 Dec 2026·Emerging Microbes & Infections

Genomic evolution and re-emergence of a multidrug-resistant Clostridioides difficile RT027 clone with reduced vancomycin susceptibility driving a prolonged hospital outbreak

Article

Author: Isidro, Joana ; Oliveira, Júlio R ; Dionísio, Filipa ; Almeida, Soraia ; Gomes, João Paulo ; Oleastro, Mónica ; Reis, Ernestina ; Santos, Manuel Mota ; Alves, Frederico ; Santos, Cláudia

Following an extended period of declining prevalence of the epidemic Clostridioides difficile ribotype 027 (RT027) in Portugal, a genetically distinct, multidrug-resistant (MDR) RT027 strain with reduced susceptibility to vancomycin has emerged, causing a 15-month outbreak. This investigation provides epidemiological and genomic evidence for renewed circulation and evolutionary adaptation of this high-risk lineage. A comprehensive outbreak investigation was conducted in a tertiary-care hospital in northern Portugal between 2023 and 2025. Epidemiological and clinical data, antimicrobial exposures, and infection-control measures were analysed. Whole-genome sequencing (WGS) was performed to characterize the outbreak clone. Sixty-six RT027 C. difficile infection (CDI) cases were confirmed, with incidence peaking at 5.46 cases per 10,000 patient-bed days in April 2024. WGS revealed an unusual accumulation of AMR determinants conferring a broad MDR phenotype. Notably, all isolates harboured the VanR T115A substitution, a rare mutation previously linked to reduced vancomycin susceptibility, raising concerns regarding evolving antimicrobial tolerance within RT027. The close relatedness to 2016-2018 USA isolates suggests a recent emergence of this clone. Transmission was facilitated by structural constraints, limited isolation capacity and shared sanitary facilities. This prolonged outbreak documents the re-emergence and genomic evolution of a hypervirulent RT027 lineage, characterized by a concerning expansion of antimicrobial resistance and decreased vancomycin susceptibility and a high recurrence rate (25%). These findings highlight the ongoing adaptive potential of C. difficile under antimicrobial pressure and underscore the need for strengthened surveillance, genomic monitoring, and infection-prevention strategies to mitigate re-establishment of epidemic RT027 strains in Europe and beyond.

31 Dec 2026·Gut Microbes

Re-establishing bile acid composition after treatment of recurrent Clostridioides difficile infection with fecal microbiota transplantation compared with oral vancomycin or a 12-strain bacterial mixture

Article

Author: Rode, Anne Abildtrup ; Gauliard, Emilie ; Lamazière, Antonin ; Nielsen, Henrik Vedel ; Humbert, Lydie ; Bytzer, Peter ; Petersen, Andreas Munk ; Helms, Morten ; Duboc, Henri ; Rainteau, Dominique ; Schønning, Kristian ; Chehri, Mahtab ; Engberg, Jørgen

Patients with Clostridioides difficile infection have high colonic levels of primary bile acids, which are potent germinators of Clostridioides difficile. Several studies have suggested that re-establishing a normal bile acid composition is a key factor in fecal microbiota transplantation (FMT) for recurrent C. difficile infection, yet former studies supporting this lacked controls. In a subgroup from a randomized controlled trial, we compared the bile acid composition in patients with recurrent C. difficile infection treated with either FMT, a bacterial mixture, or vancomycin. The fecal bile acid content was analyzed several times before and after treatments. Furthermore, we used 16S rDNA gene sequencing to analyze the presence of some bacterial species involved in bile acid metabolism. Stool donors served as healthy controls. We observed a higher proportion of primary bile acids in patients with recurrent C. difficile infection than in donors, yet a donor-like dominance of secondary bile acids was observed after successful treatment in all groups. The shift seemed to occur earliest in the FMT group, followed by the vancomycin group, and the latest in the bacterial mixture group. In approximately half of the participants, the rise in secondary bile acids was timely associated with the detection of bile acid-transforming bacteria that were absent before treatment. Our findings indicate that FMT re-establishes the bile acid composition faster than vancomycin, reducing the time of susceptibility to recurrences of C. difficile infection. Hence, bacterial mixtures developed as an alternative to donor stool for treating recurrent C. difficile infection might benefit from including bile acid-metabolizing bacteria.

31 Dec 2026·Gut Microbes

Intra-species competition combats vancomycin-resistant enterococci

Article

Author: Gefen, Tal ; Naddaf, Rawi ; Carasso, Shaqed ; Geva-Zatorsky, Naama ; Dagan, Omri ; Ben-Assa, Nadav ; Sason, Aviv

Vancomycin-resistant Enterococcus (VRE) is a leading cause of multidrug-resistant infections in hospitalized patients, yet no reproducible microbiota therapies exist to selectively displace it. Here we harness intra-species competition within Enterococcus to suppress VRE colonization. Through in vitro screening and mouse colonization models, we identified a single antibiotic-susceptible strain, E. faecalis X98, that significantly reduced VRE burden both in vitro and in mouse experiments, whereas multi-strain consortia failed due to competitive interference among consortium members. In parallel, we subjected the vancomycin-sensitive strain E. faecalis OG1RF to phage selection, which produced a prophage-integrated derivative with convergent glycosyltransferase mutations that secreted a VRE-killing factor, conferring enhanced antagonism even without exogenous phage. These findings reveal ecological and evolutionary principles for selecting strains as targeted microbial therapeutics. Exploiting intra-species antagonism and phage-driven evolution provides a practical framework for developing microbiota-based interventions that minimize collateral damage to the microbiome while addressing antibiotic-resistant pathogens.

309

News (Medical) associated with Vancomycin Hydrochloride

09 Jun 2026

·www.biospace.com

Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs

iStock, dk_photos The money will enable the addition of aseptic filling and oral solid dose capabilities to support Hikma’s products and contract manufacturing clients. Hikma is investing $267 million across two sites in Ohio as part of a $1 billion U.S. expansion drive the generic drugmaker unveiled last year. Pending approval and finalization of economic development incentives, Hikma will spend $216 million to expand oral solid dose and nasal inhalation manufacturing operations in Columbus, Ohio. Hikma, which expects the investment to create 50 jobs, broke ground on an expansion in Columbus last year. The company has been investing in the site in preparation for a long-term manufacturing contract with a global pharma company. With pharma companies wanting to relocate drug production to the U.S. amid political pressure, Hikma has identified opportunities to use its plants to build a contract manufacturing business. Hikma is spending the remaining $51 million of its recently disclosed investment to expand its injectable manufacturing capabilities at a plant in Bedford, Ohio. The investment, which Hikma said will create up to 300 jobs, covers aseptic vial filling and lyophilization, IV bag production, warehousing and distribution. Manufacturing Pharma manufacturing projected to create 19,000 jobs through 2034 The forecast makes pharma one of the fastest-growing manufacturing industries in the U.S. June 3, 2026 · 2 min read · Nick Paul Taylor Read more Improving the Bedford plant has been a multiyear project at Hikma. Bought in 2024 as part of Hikma’s $135 million acquisition of Xellia Pharmaceuticals assets, the facility needed refurbishing and upgrading to support commercial production. Hikma aims to start full commercial production in 2028, according to its annual report. The company previously targeted a 2027 start date but suffered a delay last year. With machinery set to arrive later than expected, Hikma pushed back the start of commercial production at Bedford by about six months. The company plans to use the facility to make products including Tyzavan, an antibiotic that the FDA approved last year, and to support contract manufacturing. Hikma originally bought the Bedford site in 2014 as part of its acquisition of Bedford Laboratories assets from Boehringer Ingelheim. After removing equipment from the site for use in Portuguese plants, Hikma sold some of the Bedford facilities to Xellia in 2015, only to repurchase them nine years later. The investments cement Ohio’s position as a key location for Hikma, which employs more than 1,200 in Columbus. Across its sites in Ohio and New Jersey, the manufacturer employs 2,300 people. The U.S. plants can make more than 12 billion finished doses annually.

Acquisition

28 May 2026

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA

Commercialization in China through partnership with SciClone Pharmaceuticals Expands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical market NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited. The launch follows a previously announced agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product's approval by China's National Medical Products Administration (NMPA) enables SciClone to commercialize the product in one of the world's largest and fastest-growing pharmaceutical markets. Telavancin is a patented, FDA-approved injectable anti-infective that serves as a potentially life-saving treatment for patients with serious bacterial infections, including hospital-acquired and ventilator-associated pneumonia. The therapy is designed to treat infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. "Launching telavancin in China marks a significant milestone in advancing our mission of providing unique products that improve the quality of patient care," said A.J. Kazimi, Cumberland Pharmaceuticals CEO. "Through our partnership with SciClone, we are expanding access to this important therapy and providing physicians in China with a valuable new option to treat serious, difficult-to-manage infections." Antimicrobial resistance continues to be a critical global health challenge, reducing the effectiveness of many existing antibiotics and increasing the need for innovative treatments. Telavancin was specifically designed to address resistant pathogens, offering potent activity against difficult-to-treat infections. Mr. Zhao Hong, President and Chief Executive Officer of SciClone Pharmaceuticals, stated, "The successful launch of telavancin for injection in China represents another important milestone for SciClone Pharmaceuticals in the anti-infective field. Currently, MRSA remains a serious challenge and poses a significant clinical threat, particularly in respiratory tract infections, especially those that are hospital-acquired. With its unique dual bactericidal mechanism, broad antibacterial spectrum, and once-daily dosing regimen, telavancin offers an important new anti-infective option for Chinese patients with severe infections, delivering both improved efficacy and clinical convenience. Looking ahead, SciClone Pharmaceuticals will continue to focus on severe infection and oncology, address unmet medical needs, and accelerate the launch of more innovative products in China to contribute to the 'Healthy China 2030' initiative." About Vibativ ® Vibativ® (telavancin) injection was discovered in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (S. aureus) and other Gram-positive bacteria, including MRSA and MSSA. It is a once-daily, injectable lipoglycopeptide antibiotic with in vitro potency, bactericidal activity within six hours and penetration into target infection sites. The drug is approved in the U.S. and Saudi Arabia for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable. In addition, telavancin is approved in the U.S. and Saudi Arabia for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of Gram-positive bacteria, including S. aureus, both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains. The product labeling also describes the use of telavancin in treating patients whose pneumonia or skin infection is complicated by concurrent bacteremia. The product's proven efficacy against difficult-to-treat Gram-positive infections has been demonstrated in several large, multinational registrational studies, which involved one of the largest cohorts of patients with S. aureus infections studied to date. Importantly, these studies demonstrated significantly higher cure rates for telavancin as compared to vancomycin in HABP/VABP due to any single Gram-positive pathogen or S. aureus with vancomycin MIC ≥1 µg/mL. Additionally, there is extensive and well-documented evidence of the drug's in vitro potency and in vivo activity against a broad collection of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. For full prescribing information, including important safety information, visit . About SciClone Pharmaceuticals SciClone Pharmaceuticals (Holdings) Limited ("SciClone Pharmaceuticals") is a global biopharmaceutical company with an integrated platform for the development and commercialization of innovative therapies for cancer and severe infection. With an innovation-driven strategic transformation, SciClone Pharmaceuticals has established a product portfolio with differentiated advantages, including a number of first-in-class and best-in-class potential products / pipelines. Staying true to its original aspiration of "SciClone gives life hope," SciClone Pharmaceuticals is dedicated to improving patients' health by providing top-tier health care products and services with global standards of care. For more information regarding SciClone Pharmaceuticals, please visit: . For SciClone press contacts please reach out to [email protected]. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on developing innovative products that improve the quality of patient care. The company is advancing a clinical pipeline of late stage product candidates across multiple therapeutic areas with significant unmet medical needs. For more information, please visit . FORWARD LOOKING STATEMENTS: This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "goal", "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include risks and uncertainties related to the strategic transaction, risks related to our ability to develop our pipeline of new product candidates, macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the Company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

05 May 2026

·www.biospace.com

TSRL Contributes to New Publication Highlighting Promising Antibacterial Candidate for Resistant Hospital Infections

ANN ARBOR, Mich. (May 4, 2026) — TSRL, Inc., a preclinical CRO specializing in drug delivery & PK/ADME testing services and early-stage development strategies, today announced its contribution to a newly published study in Microbiology Spectrum by the American Society of Microbiology (ASM) evaluating the in vitro activity of MRS-2541, a novel methionyl-tRNA synthetase inhibitor designed to target serious gram-positive hospital infections. Additionally, it follows a 2024 publication in Antimicrobial Agents and Chemotherapy on the same lead candidate. The new publication, titled “In vitro activity of MRS-2541, a novel MetRS inhibitor, against a selection of resistant gram-positive organisms associated with serious hospital infections,” highlights the growing need for new antibacterial agents capable of addressing resistant pathogens in clinical settings. MRS-2541 demonstrated strong activity across a broad panel of gram-positive organisms, including methicillin-resistant Staphylococcus aureus and vancomycin-intermediate strains. In multiple comparisons, the compound showed greater potency than widely used antibiotics such as vancomycin, linezolid, and daptomycin. The study also reported strong activity against Enterococcus faecalis and Enterococcus faecium , including vancomycin-resistant strains, further supporting its potential as a future therapeutic option. “These findings reinforce the importance of continued innovation in antibacterial research,” said Dr. Elke Lipka, President and CEO of TSRL and board member of the Preclinical Drug Development Platform (PCDDP) at North-West University in South Africa. “Programs like this require a clear understanding of compound behavior, careful study design, and the ability to translate data into meaningful development decisions. That is where experienced preclinical teams can make a real difference.” Performed in collaboration with the University of Washington, the study highlights TSRL’s role in supporting early-stage programs that address complex therapeutic challenges. Through integrated capabilities in bioanalysis, formulation development, pharmacokinetics, and toxicology, TSRL works with biotech, pharmaceutical, and academic partners to advance promising compounds toward clinical readiness. As antibiotic resistance continues to rise globally, the identification and development of new treatment options remain a priority for researchers and healthcare providers alike. The results from this study support further investigation of MRS-2541 as a potential option for serious infections caused by resistant gram-positive bacteria. Frederick S. Buckner, MD, Professor in the Department of Medicine, Division of Allergy & Infectious Diseases at the University of Washington School of Medicine, said, “TSRL will make an outstanding team to bring forward much needed therapeutics to combat the spreading problem of multi-drug resistant infectious diseases.” Read the full publication here: About TSRL TSRL, Inc. is a preclinical contract research organization (CRO) specializing in oral drug delivery, formulation development, and drug absorption strategies. Based in Michigan, TSRL supports pharmaceutical, biotechnology, and government partners with a science-first approach that goes beyond standard testing. With expertise spanning in vitro and in vivo models, solubility enhancement, and strategic consulting, TSRL helps advance complex drug candidates from early discovery through IND-enabling studies. Learn more at . Media Contact Don F. McLean, McLean Media +1-734-716-4182

Microbial therapyClinical Result

100 Deals associated with Vancomycin Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00926	Vancomycin Hydrochloride	J01XA01 A07AA09 S01AA28	DB00512

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Clostridium difficile diarrhea	United States	Hikma Pharmaceuticals USA, Inc.	26 Aug 2021
Blepharitis	Japan	TOA Pharmaceuticals Co., Ltd.	16 Oct 2009
Conjunctivitis	Japan	TOA Pharmaceuticals Co., Ltd.	16 Oct 2009
Dacryocystitis	Japan	TOA Pharmaceuticals Co., Ltd.	16 Oct 2009
(non-specific) purulent meningitis	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Arthritis	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Empyema	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Endocarditis, Bacterial	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Hemorrhagic Septicemia	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Lung Abscess	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Neutropenia	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Osteomyelitis	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Pneumonia	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Secondary infection	Japan	OHKURA Pharmaceutical Co., Ltd.	22 Oct 2004
Bone and joint infections	United States	Baxter Healthcare Corp.	29 Apr 1993
Endocarditis	United States	Baxter Healthcare Corp.	29 Apr 1993
Infectious Diseases	United States	Baxter Healthcare Corp.	29 Apr 1993
Lower Respiratory Tract Infections	United States	Baxter Healthcare Corp.	29 Apr 1993
Sepsis	United States	Baxter Healthcare Corp.	29 Apr 1993
Skin and skin structure infections	United States	Baxter Healthcare Corp.	29 Apr 1993

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystic Fibrosis	Phase 3	United States	Savara, Inc.	20 Sep 2017
Cystic Fibrosis	Phase 3	Canada	Savara, Inc.	20 Sep 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	United States	Savara, Inc.	20 Sep 2017
MRSA - Methicillin resistant Staphylococcus aureus infection	Phase 3	Canada	Savara, Inc.	20 Sep 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04666948 (BENEFICIAL, Pubmed \| Lancet Child Adolesc Health)	Phase 4	Gram-Positive Bacterial Infections	314	Vancomycinvancomycin (Model-informed precision dosing (MIPD) of vancomycin)	iopveishlc(ozqgxjsbiz) = oxllfmahji muyelfruut (railxsvbfh )	Positive	01 Jun 2026
				Vancomycinvancomycin (Standard-of-care therapeutic drug monitoring (TDM) of vancomycin)	iopveishlc(ozqgxjsbiz) = ssjmpdbpys muyelfruut (railxsvbfh )
NCT02227446 (Pubmed \| JAMA)	Phase 3	Surgical Wound Infection	1,528	Intrawound Tobramycin (1.2 g) plus Vancomycin (1.0 g) powder	ybpbpfmrrg(ththbmzyws) = yljvxlexfw digrumhnwn (muvuxvlhlw )	Negative	12 May 2026
				Intrawound Vancomycin (1.0 g) powder	ybpbpfmrrg(ththbmzyws) = vwwejcwbgc digrumhnwn (muvuxvlhlw )
NCT02631408 (Pubmed \| Global Spine J)	Phase 4	Surgical Wound Infection	292	intrawound vancomycin powder (1 g) plus standard prophylaxis	wkwyhmfhpx(xsdtnmwpvr) = mwdyilrrzv anlscybhcl (tsaveupzjm ) View more	Positive	08 May 2026
				standard prophylaxis alone	wkwyhmfhpx(xsdtnmwpvr) = gwobtnagmz anlscybhcl (tsaveupzjm )
NCT05156437 (OPTIMAL, CTgov)	Phase 4	Endocarditis	5	Cefalexin+Levofloxacin+Amoxycillin+Oxacillin+Ceftriaxone+Dicloxacillin+Rifampicin+Ampicillin+Linezolid+Daptomycin+Vancomycin (Group I (Experimental))	fyjwlxrkvy(guqjxbhvdt) = zutluqqqpu nekildtjca (wwaookwkgs, rtiiqkjcod - wwiaexmnyy) View more	-	05 May 2026
				Oxacillin+Ceftriaxone+Ampicillin+Daptomycin+Vancomycin (Group II (Control Group))	fyjwlxrkvy(guqjxbhvdt) = yrtbrhgmue nekildtjca (wwaookwkgs, eruufmrjal - lbbaxvlxhg) View more
NCT03710122 (CTgov)	Phase 2/3	Cholangitis, Sclerosing	102	Vancomycin (Vancomycin)	ijecnvrreo(nszfvyzgax) = tecdenwcnj ipwpkdvmio (oyaojovseh, pgqumsfqgi - fsijmufyrx) View more	-	22 Apr 2026
				Placebo (Placebo)	ijecnvrreo(nszfvyzgax) = falrhyxtmw ipwpkdvmio (oyaojovseh, inrqtgcshr - ixszkmtjyt) View more
NCT04662632 (APEX, CTgov)	Phase 2	Prosthetic joint infection \| Juvenile Polyposis Syndrome	76	VT+Tobramycin+Tobramycin Sulfate+VT-X7+vancomycin hydrochloride (VT-X7)	ixnmloluvu = iabztomvwq ufjutbvnhk (sfuyshecon, nlulfhztkj - awcmvlpagr) View more	-	21 Apr 2026
				antibiotics (Standard of Care)	ixnmloluvu = culipkwwvx ufjutbvnhk (sfuyshecon, mackhelyda - fffgnssiby) View more
NCT03030248 (CTgov)	Phase 2	Hematologic Neoplasms \| Clostridium difficile infection	9	Vancomycin Oral Capsule (Vancomycin Treated Group)	lpywyffpky(egkgzfctmi) = jzscabmrpm qygwqqvnut (xnelrnkyul, 79994345.79) View more	-	15 Apr 2026
				Placebo Oral Capsule (Placebo Group)	lpywyffpky(egkgzfctmi) = zdhwbaardr qygwqqvnut (xnelrnkyul, 80000000.00) View more
NCT04138706 (Pubmed \| JAMA Netw Open)	Phase 3	Clostridium difficile infection	265	Vancomycin pulse and taper regimen	vmutlfhbri(wnuxwsopxt) = kjojrigxtr wvzyhbhjaw (pgdwxtikmy ) View more	Positive	27 Feb 2026
				Placebo	vmutlfhbri(wnuxwsopxt) = iylvjfzjrx wvzyhbhjaw (pgdwxtikmy ) View more
ECCO2026	Not Applicable	Cholangitis, Sclerosing	614	Oral Vancomycin (OVT)	qbeysgvnuh(ctjjdowhsh) = uisbagtofn djmavxbqql (ovypfpnnxa, 72.0 - 95.3) View more	Positive	18 Feb 2026
				Biologic-only	qbeysgvnuh(ctjjdowhsh) = qssyxobxsx djmavxbqql (ovypfpnnxa, 28.0 - 80.2) View more
NCT04075526 (CTgov)	Phase 1	Osteoarthritis \| Infectious Diseases	2,129	Povidone iodine+Vancomycin powder (Povidone Iodine and Vancomycin Powder)	ovborfhftm = denrmshhqh xzsyliizuj (yyihzeztdd, jwvtmlayth - egnedprvnl) View more	-	17 Feb 2026
				Povidone iodine (Povidone Iodine Alone)	ovborfhftm = rqmpqsikcm xzsyliizuj (yyihzeztdd, wkbidvmapz - jwxlbtsjwu) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis